Compare TDOC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | DRUG |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.2M | 856.4M |
| IPO Year | 2015 | 2020 |
| Metric | TDOC | DRUG |
|---|---|---|
| Price | $5.29 | $80.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $7.40 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 5.7M | 73.1K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,406,840,000.00 | N/A |
| Revenue This Year | $1.74 | N/A |
| Revenue Next Year | $1.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $23.18 |
| 52 Week High | $9.77 | $123.75 |
| Indicator | TDOC | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 51.66 | 48.24 |
| Support Level | $4.44 | $77.80 |
| Resistance Level | $5.49 | $91.00 |
| Average True Range (ATR) | 0.27 | 4.77 |
| MACD | 0.12 | -0.62 |
| Stochastic Oscillator | 80.02 | 40.88 |
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with improved convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.